Psoriatic Arthritis News

SCOTTSDALE, Ariz. —Rheumatologists, focused as they are on inflammatory symptoms, are often less familiar with cardiovascular management, according to M. Elaine Husni, MD, MPH, of the Cleveland Clinic.

Psoriatic arthritis is often a painful comorbidity for patients with psoriasis — and an expensive one at that. A 2016 study published in Actas Dermo-Sifiliográficas found the disease comes with a price tag to the tune of US$15,000 per patient in Europe. However, that price is also based on biologic drug use that can be as much as 80% cheaper than those in the United States or Canada.

Approximately 35% of relevant industry payments to U.S.-based authors of American College of Rheumatology clinical practice guidelines remain undisclosed, according to findings published in Arthritis & Rheumatology.

Patients with psoriasis carry a slightly increased risk for cancer, particularly keratinocyte cancer and lymphomas, according to data published in JAMA Dermatology.

MAUI, Hawaii — The past year was marked by an increase in head-to-head drug trials in psoriatic arthritis, according to a presentation at the 2020 Rheumatology Winter Clinical Symposium.

MAUI, Hawaii — A novel TYK2 inhibitor may provide clinicians with another treatment option along the janus kinase pathway in patients with severe psoriasis, according to a presentation at the 2020 Rheumatology Winter Clinical Symposium.

The use of biologic therapy to treat psoriasis and psoriatic arthritis has increased over time along with the use of systemic corticosteroids, according to a letter published in the Journal of the American Academy of Dermatology.

A significant proportion of patients with psoriatic arthritis experience a prodromal period, as early as 5 years prior to diagnosis, characterized by musculoskeletal symptoms and an increase in health care use and costs, according to data published in Arthritis Care & Research.

There is an increased risk for developing inflammatory arthritis among patients with hidradenitis suppurativa, according to a population-based cohort study published in JAMA Dermatology.

Approximately 66% of adults with psoriatic arthritis waited 6 months or more for their diagnosis after first seeking medical attention, with about 32.5% waiting 5 years or more, according survey findings published in BMC Rheumatology.